Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:AVTX NASDAQ:DBVT NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$9.80+4.7%$9.32$1.47▼$14.53$231.35M2.38647,106 shs479,514 shsAVTXAvalo Therapeutics$17.83+4.4%$15.65$4.50▼$24.27$937.25M0.831.59 million shs1.97 million shsDBVTDBV Technologies$16.11+2.6%$18.77$8.51▼$26.18$929.63M-0.99298,783 shs376,501 shsREPLReplimune Group$11.42+2.1%$5.67$1.50▼$13.24$923.16M0.916.18 million shs2.96 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+4.70%+9.99%+24.52%+79.49%+504.94%AVTXAvalo Therapeutics+4.39%+24.42%+9.05%+27.81%+272.23%DBVTDBV Technologies+2.61%-3.82%-11.39%-20.52%+88.20%REPLReplimune Group+2.15%+30.07%+132.59%+51.06%+23.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$9.80+4.7%$9.32$1.47▼$14.53$231.35M2.38647,106 shs479,514 shsAVTXAvalo Therapeutics$17.83+4.4%$15.65$4.50▼$24.27$937.25M0.831.59 million shs1.97 million shsDBVTDBV Technologies$16.11+2.6%$18.77$8.51▼$26.18$929.63M-0.99298,783 shs376,501 shsREPLReplimune Group$11.42+2.1%$5.67$1.50▼$13.24$923.16M0.916.18 million shs2.96 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+4.70%+9.99%+24.52%+79.49%+504.94%AVTXAvalo Therapeutics+4.39%+24.42%+9.05%+27.81%+272.23%DBVTDBV Technologies+2.61%-3.82%-11.39%-20.52%+88.20%REPLReplimune Group+2.15%+30.07%+132.59%+51.06%+23.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.83Moderate Buy$39.00297.96% UpsideAVTXAvalo Therapeutics 2.85Moderate Buy$46.67161.73% UpsideDBVTDBV Technologies 2.88Moderate Buy$48.50201.06% UpsideREPLReplimune Group 1.70Reduce$4.88-57.31% DownsideCurrent Analyst Ratings BreakdownLatest ARTV, DBVT, REPL, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026AVTXAvalo Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$58.006/15/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/12/2026AVTXAvalo Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$41.006/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.005/29/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$8.005/26/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/14/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$62.00 ➝ $55.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K969.02N/AN/A$4.48 per share2.19AVTXAvalo Therapeutics$59K15,885.62N/AN/A$4.49 per share3.97DBVTDBV Technologies$5.64M169.13N/AN/A$4.20 per share3.84REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$83.86M-$3.54N/AN/AN/AN/A-73.15%-62.74%8/5/2026 (Estimated)AVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)DBVTDBV Technologies-$146.95M-$4.46N/AN/AN/A-2,895.37%-129.88%-88.84%7/29/2026 (Estimated)REPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/25/2026 (Estimated)Latest ARTV, DBVT, REPL, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/25/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$5.57 millionN/A5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/8/2026Q1 2026ARTVArtiva Biotherapeutics-$0.88-$0.95-$0.07-$0.95N/AN/A4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 million3/26/2026Q4 2025DBVTDBV Technologies-$0.1935-$1.15-$0.9565-$4.43$1.06 million$0.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A8.168.16AVTXAvalo TherapeuticsN/A7.667.66DBVTDBV TechnologiesN/A4.764.76REPLReplimune Group0.335.605.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AAVTXAvalo Therapeutics87.06%DBVTDBV Technologies71.74%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%AVTXAvalo Therapeutics4.46%DBVTDBV Technologies1.06%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.72 million19.43 millionN/AAVTXAvalo Therapeutics4052.57 million50.22 millionNot OptionableDBVTDBV Technologies8059.21 million58.58 millionOptionableREPLReplimune Group21082.57 million78.28 millionOptionableARTV, DBVT, REPL, and AVTX HeadlinesRecent News About These CompaniesReplimune: Modeling The Coin Flip Of FDA ApprovalJune 4, 2026 | seekingalpha.comInsider Selling: Replimune Group (NASDAQ:REPL) Insider Sells 12,000 Shares of StockJune 4, 2026 | insidertrades.comReplimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...June 1, 2026 | finanznachrichten.deReplimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...June 1, 2026 | finanznachrichten.deWhy Is REPL Stock Gaining In Pre-Market Today?June 1, 2026 | finance.yahoo.comREPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugJune 1, 2026 | zacks.comReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral ...May 31, 2026 | caledonianrecord.comCReplimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026May 31, 2026 | quiverquant.comQReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 31, 2026 | globenewswire.comStock Movers: Dell, Replimune, SnowflakeMay 30, 2026 | bloomberg.comReplimune soars after FDA reconsiders denial of cancer drugMay 30, 2026 | msn.comReplimune gets third chance at US approval for skin cancer drugMay 30, 2026 | msn.comHow Replimune’s drug got third chance after White House interventionMay 30, 2026 | msn.comReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 30, 2026 | globenewswire.comHow Replimune's drug got a third chance after the White House intervenedMay 29, 2026 | wsj.comReplimune to resubmit twice-rejected drug for approval after FDA shakeupMay 29, 2026 | cnbc.comReplimune Group, Inc. Announces FDA Alignment on Path Forward for BLA Resubmission of RP1 for Advanced Melanoma TreatmentMay 29, 2026 | quiverquant.comQReplimune reaches agreement with US FDA to resubmit melanoma drug applicationMay 29, 2026 | reuters.comReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAMay 29, 2026 | globenewswire.comReplimune Gets Third Try at FDA Approval After Makary DepartureMay 29, 2026 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTV, DBVT, REPL, and AVTX Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$9.80 +0.44 (+4.70%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$9.81 +0.01 (+0.06%) As of 08:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Avalo Therapeutics NASDAQ:AVTX$17.83 +0.75 (+4.39%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$18.05 +0.22 (+1.21%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.DBV Technologies NASDAQ:DBVT$16.11 +0.41 (+2.61%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$16.16 +0.05 (+0.31%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Replimune Group NASDAQ:REPL$11.42 +0.24 (+2.15%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$11.41 -0.01 (-0.09%) As of 08:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
